India’s Healthify Eyes More Weight‑Loss Drugmaker Tie‑ups After Novo Nordisk Pact

Indian health‑tech startup Healthify is looking to expand partnerships with manufacturers of weight‑loss drugs following its inaugural pact with Novo Nordisk’s India unit, its CEO said. The new deal marks Healthify’s first collaboration with a pharmaceutical company. Through this agreement, Healthify has rolled out a patient‑support programme that gives users prescribed Novo Nordisk’s therapies access to personalized health, nutrition, and lifestyle coaching. According to CEO Tushar Vashisht, the startup’s ambition is to become the world’s largest patient‑support provider for all companies offering GLP‑1 receptor‑agonist drugs globally. Healthify currently boasts roughly 45 million users worldwide, and its paid subscriber base is in the six‑figure range (though the company didn’t disclose exact numbers). The firm said its GLP‑1 weight‑loss programme is its fastest‑growing product, and expects over one‑third of paid subscriptions to come from this programme within the next 12 months — driven by both new sign‑ups and upgrades from existing users. With rising demand for obesity treatments, India is a key battleground. Global competition is heating up as players like Eli Lilly vie for market share, and looming patent expirations (e.g., for semaglutide in 2026) open the door to generics — likely intensifying competition. Having raised roughly US $122 million so far, Healthify plans to extend its drug‑linked support services to more geographies beyond India, though details remain under wraps. #Healthify #WeightLossDrugs #GLP1 #ObesityTreatment #SlimScan #GrowthStocks #CANSLIM